Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot study of the safety and efficacy of quadrivalent human papillomavirus vaccine (Gardasil) in female subjects with juvenile idiopathic arthritis (JIA)/ seronegative arthritis.

X
Trial Profile

Pilot study of the safety and efficacy of quadrivalent human papillomavirus vaccine (Gardasil) in female subjects with juvenile idiopathic arthritis (JIA)/ seronegative arthritis.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Human papillomavirus infections; Juvenile rheumatoid arthritis
  • Focus Pharmacodynamics
  • Acronyms CHASE
  • Most Recent Events

    • 13 Dec 2020 Status changed from active, no longer recruiting to completed.
    • 04 Mar 2018 Planned End Date changed from 1 Nov 2014 to 30 Sep 2018.
    • 04 Mar 2018 Planned primary completion date changed from 1 Nov 2014 to 30 Jun 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top